Zirong Li

Mr. Zirong Li

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
ZLZhenyu Lin
Zhenyu Lin
WCWenjie Cai
Wenjie Cai
WHWentai Hou
Wentai Hou
YCYayuan Chen
Yayuan Chen
BGBingzong Gao
Bingzong Gao
ZLZirong Li
Zirong Li
Survival prediction of esophageal cancer is an essential task for doctors to make personalized cancer treatment plans. However, handcrafted features from medical images need prior medical knowledge, which is usually limited and not complete, yielding unsatisfying survival predictions. To address these challenges, we propose a novel and efficient deep learning-based survival prediction framework for evaluating clinical outcomes before concurrent chemoradiotherapy. The proposed model consists of two key components: a 3D Coordinate Attention Convolutional Autoencoder (CACA) and an uncertainty-based jointly Optimizing Cox Model (UOCM). The CACA is built upon an autoencoder structure with 3D coordinate attention layers, capturing latent representations and encoding 3D spatial characteristics with precise positional information. Additionally, we designed an Uncertainty-based jointly Optimizing Cox Model, which jointly optimizes the CACA and survival prediction task. The survival prediction task models the interactions between a patient’s feature signatures and clinical outcome to predict a reliable hazard ratio of patients. To verify the effectiveness of our model, we conducted extensive experiments on a dataset including computed tomography of 285 patients with esophageal cancer. Experimental results demonstrated that the proposed method achieved a C-index of 0.72, outperforming the state-of-the-art method.

20 November 2021 in Medical Physics
Verified
Journal Article
Open access
PDF file
DWDandan Wang
Dandan Wang
YYYueju Yin
Yueju Yin
QZQichao Zhou
Qichao Zhou
ZLZirong Li
Zirong Li
XMXingmin Ma
Xingmin Ma
ZJZhu Jian
Zhu Jian
Purpose: To identify dosimetric parameters associated with acute hematological toxicity (HT) and identify the corresponding normal tissue complication probability (NTCP) model in cervical cancer patients receiving helical tomotherapy (Tomo) or fixed‐field intensity‐modulated radiation therapy (ff‐IMRT) in combination with chemotherapy, that is, concurrent chemoradiotherapy (CCRT) using the Lyman–Kutcher–Burman normal tissue complication probability (LKB‐NTCP) model.Methods: Data were collected from 232 cervical cancer patients who received Tomo or ff‐IMRT from 2015 to 2018. The pelvic bone marrow (PBM) (including the ilium, pubes, ischia, acetabula, proximal femora, and lumbosacral spine) was contoured from the superior boundary (usually the lumbar 5 vertebra) of the planning target volume (PTV) to the proximal end of the femoral head (the lower edge of the ischial tubercle). The parameters of the LKB model predicting ≥grade 2 hematological toxicity (Radiation Therapy Oncology Group [RTOG] grading criteria) (TD50(1), m, and n) were determined using maximum likelihood analyses. Univariate and multivariate logistic regression analyses were used to identify correlations between dose–volume parameters and the clinical factors of HT.Results: In total, 212 (91.37%) patients experienced ≥grade 2 hematological toxicity. The fitted normal tissue complication probability model parameters were TD50(1) = 38.90 Gy (95%CI, [36.94, 40.96]), m = 0.13 (95%CI [0.12, 0.16]), and n = 0.04 (95%CI [0.02, 0.05]). Per the univariate analysis, the NTCP (the use of LKB‐NTCP with the set of model parameters found, p = 0.023), maximal PBM dose (p = 0.01), mean PBM dose (p = 0.021), radiation dose (p = 0.001), and V16–53 (p < 0. 05) were associated with ≥grade 2 HT. The NTCP (the use of LKB‐NTCP with the set of model parameters found, p = 0.023; AUC = 0.87), V16, V17, and V18 ≥ 79.65%, 75.68%, and 72.65%, respectively (p < 0.01, AUC = 0.66∼0.68), V35 and V36 ≥ 30.35% and 28.56%, respectively (p < 0.05; AUC = 0.71), and V47 ≥ 13.43% (p = 0.045; AUC = 0.80) were significant predictors of ≥grade 2 hematological toxicity from the multivariate logistic regression analysis.Conclusions: The volume of the PBM of patients treated with concurrent chemoradiotherapy and subjected to both low‐dose (V16–18) and high‐dose (V35,36 and V47) irradiation was associated with hematological toxicity, depending on the fractional volumes receiving the variable degree of dosage. The NTCP were stronger predictors of toxicity than V16–18, V35, 36, and V47. Hence, avoiding radiation hot spots on the PBM could reduce the incidence of severe HT.

25 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ZLZirong Li
Zirong Li
ARAnn C. Raldow
Ann C. Raldow
JWJoanne Weidhaas
Joanne Weidhaas
QZQichao Zhou
Qichao Zhou
XQX. Sharon Qi
X. Sharon Qi
Locally advanced rectal cancer (LARC) presents a significant challenge in terms of treatment management, particularly with regards to identifying patients who are likely to respond to radiation therapy (RT) at an individualized level. Patients respond to the same radiation treatment course differently due to inter- and intra-patient variability in radiosensitivity. In-room volumetric cone-beam computed tomography (CBCT) is widely used to ensure proper alignment, but also allows us to assess tumor response during the treatment course. In this work, we proposed a longitudinal radiomic trend (LRT) framework for accurate and robust treatment response assessment using daily CBCT scans for early detection of patient response. The LRT framework consists of four modules: (1) Automated registration and evaluation of CBCT scans to planning CT; (2) Feature extraction and normalization; (3) Longitudinal trending analyses; and (4) Feature reduction and model creation. The effectiveness of the framework was validated via leave-one-out cross-validation (LOOCV), using a total of 840 CBCT scans for a retrospective cohort of LARC patients. The trending model demonstrates significant differences between the responder vs. non-responder groups with an Area Under the Curve (AUC) of 0.98, which allows for systematic monitoring and early prediction of patient response during the RT treatment course for potential adaptive management.

1 April 2021 in Journal of Biomechanics
Verified
Journal Article
Closed access
CFChenglong Feng
Chenglong Feng
LWLizhen Wang
Lizhen Wang
PXPeng Xu
Peng Xu
ZCZhaowei Chu
Zhaowei Chu
JYJie Yao
Jie Yao
Yubo FanYubo Fan
Yubo Fan

21 May 2025 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JDJianming Ding
Jianming Ding
XYXiaoyan Yin
Xiaoyan Yin
YLYuhao Lin
Yuhao Lin
XLXiyi Liao
Xiyi Liao
LCLisha Chen
Lisha Chen
ZFZhaodong Fei
Zhaodong Fei